Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.

A, Awada; T, Gil; N, Whenham; Hamme J, Van; T, Besse-Hammer; E, Brendel; H, Delesen; MC, Joosten; CD, Lathia; BA, Loembé; M, Piccart-Ghebart; A, Hendlisz

doi:10.1177/0091270010386226

Public

Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.

Published in Journal of clinical pharmacology • Jan 5, 2011

Authors:

Awada A

Gil T

Whenham N

Abstract

Sorafenib (twice daily [bid]) plus capecitabine (2 weeks on schedule/1 week off schedule) safety and pharmacokinetics were investigated in patients with advanced solid tumors (N = 35). Cohort 1 (n = 13) included sorafenib 200 mg bid and capecitabine 1050 mg/m(2) bid; cohort 2 (n = 4), sorafenib 400 ...

View

Paywalled

View Full Text

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Generate AI Take for this paper

Discussions